Healthcare Industry News: peripheral artery disease
News Release - March 31, 2008
NovoStent Announces Implantation of World's Longest Peripheral StentMOUNTAIN VIEW, Calif.--(HSMN NewsFeed)--NovoStent Corporation, a privately held medical device company, announced today that physicians in Germany have implanted 250 mm stents as part of the company’s European clinical trial evaluating the use of NovoStent’s peripheral stent in the treatment of superficial femoral and popliteal artery disease.
The first case with the 250 mm stent was performed by Drs. Sven Braunlich and Dierk Scheinert in Leipzig, Germany. Dr. Scheinert, Head of the Department of Angiology at the University of Leipzig Heart Center and Park Hospital, is the principal investigator in NovoStent’s multi-center European study. “It is exciting to be the first center to implant the world's longest peripheral stent,” said Dr Scheinert. “The stent is more flexible than any other that I have used which is critical since stents used to treat real world, long peripheral lesions have been shown to be more prone to fracture and restenosis.”
Dr. Thomas Zeller, the Director of the Department of Vascular Medicine, at the Heart Center in Bad Krozingen, Germany, also implanted the device and commented, “I was impressed with the exact placement of such a long stent and the optimal clinical outcome for my patient.”
NovoStent has developed a novel, self-expanding stent technology to provide a wide range of vascular and non-vascular therapies. The treatment of femoropopliteal disease is the first vascular application of NovoStent’s technology. “The ability to deliver an extremely long stent is just one of the unique aspects of our technology platform and will help facilitate the evolution of patient care relative to the treatment of longer lesions,” said G. Ray Martin, PhD, President and CEO of NovoStent. Dr. Martin added, “The 250 mm device is a natural extension of our clinical offering that has been used to treat over 60 patients for which we are starting to receive exciting 6-month follow up data.”
Dr. Hugo Londero, Chief of Hemodynamics and Transcatheter Interventional Services at Sanatorio Allende in Cordoba, Argentina, was the first physician to implant NovoStent devices in the SFA as well as the popliteal artery. Physicians have previously avoided placing stents in the popliteal artery for fear of stent fractures.
The company’s stents employ a helical macrostructure to maximize flexibility, durability, and radial strength in addition to a micro-cell structure that can be customized for different vascular and non-vascular anatomies to achieve optimal lumen coverage and prolapse control. NovoStent's unique stent and integrated delivery system are designed to provide easy deployment and accurate delivery.
Approximately 12 million Americans are afflicted with peripheral artery disease (PAD). PAD commonly causes blockages in the leg arteries, which can result in pain when walking or even resting. NovoStent is a pioneering medical device company that seeks to provide options for patients wishing to avoid surgery to treat their leg pain.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.